-+ 0.00%
-+ 0.00%
-+ 0.00%

Silo Pharma Files Patent Application With USPTO For SPC-14, Intranasal Compound Exclusively Licensed AD Drug

Benzinga·04/28/2025 11:52:55
Listen to the news

Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer's disease (AD) exclusively licensed to Silo Pharma from Columbia University. 

SPC-14 was developed under a sponsored research agreement with Columbia University. In 2024, Silo entered into an exclusive global license agreement with Columbia University under which it is authorized to further develop, manufacture, and commercialize the drug SPC-14.